Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Shebli Atrash
Academic and Community Cancer Research United
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hackensack University Medical Center
Hackensack, New Jersey, United States
- State University of New York Upstate Medical University
Syracuse, New York, United States
- Unc Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
- Carolinas Medical Center/levine Cancer Institute
Charlotte, North Carolina, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 8 Dec 2022
- Primary completion
- 30 Sept 2024
- Completion
- 30 Dec 2027
- Last update posted
- 26 Sept 2024
- Registered enrollment
- 52
- Registry id
- NCT04756401
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.